# FDA Grants Accelerated Approval to BMS Zenbexus, First-in-Class CELMoD, for Relapsed Multiple Myeloma

> fda · REPORTED · 2026-08-13

On August 13, 2026, the FDA granted accelerated approval to Bristol Myers Squibb's Zenbexus (iberdomide) in combination with daratumumab, hyaluronidase-fihj, and dexamethasone for adults with multiple myeloma who received at least one prior line of therapy, making it the first FDA-approved cereblon E3 ligase modulator and the first drug approved in myeloma based on minimal residual disease-negative complete response. The approval allows use as early as first relapse.

About Bristol Myers Squibb: Bristol Myers Squibb is a global biopharmaceutical company; Zenbexus (iberdomide) is its first CELMoD therapy, an oral targeted protein degrader developed for relapsed or refractory multiple myeloma patients.

- Company: Bristol Myers Squibb
- Sector: oncology
- Primary source: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.